E-merge - Evaluation of MEpolizumab-based regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized, controlled, double-blind study
The E-merge study is looking for a better way to treat a rare condition called Eosinophilic Granulomatosis with Polyangiitis (EGPA), which used to be known as Churg-Strauss syndrome. This condition causes inflammation in different parts of the body. The study will compare a new treatment approach that includes a drug called mepolizumab (also known as Nucala) against the usual treatments. The main goal is to find out if this new approach can help people with EGPA take less of a steroid medication called prednisone, without their symptoms getting worse (a 'relapse'). It's hoped this could improve their quality of life by reducing steroid side effects.
Em resumo
Sobre o que é este estudo?
The E-merge study is a research project designed to find the most effective way to treat a rare illness called Eosinophilic Granulomatosis with Polyangiitis (EGPA), which was previously known as Churg-Strauss syndrome. EGPA is a long-term condition that causes inflammation in various organs, including the lungs, skin, heart, and nerves. Many people with EGPA need to take steroid medications like prednisone for a long time, which can have side effects.
This study aims to discover if a treatment plan involving a drug called mepolizumab (brand name Nucala) is better at helping patients reduce their daily dose of prednisone to a low level (4 mg or less) without their EGPA flaring up again. Mepolizumab is a drug that helps reduce certain types of white blood cells called eosinophils, which are often too high in people with EGPA.
The study will compare this mepolizumab-based treatment with the standard treatments currently used for EGPA. By doing this, researchers hope to improve how EGPA is managed, helping patients feel better and potentially lowering the risks associated with long-term steroid use. This is a "Phase III" study, which means it's one of the final steps before a new treatment might become widely available.
Pontos principais
- This study tests a new treatment idea for EGPA to reduce reliance on steroids.
- It compares mepolizumab-based treatment with standard care.
- The main goal is to help patients lower their prednisone dose without relapse.
- Participation involves regular clinic visits and close health monitoring.
- This is a 'Phase III' study, a crucial step before a new treatment can be widely approved.
Quem pode ser elegível?
This study is looking for adults aged 18 years and older who have been diagnosed with Eosinophilic Granulomatosis with Polyangiitis (EGPA).
Both men and women can take part in this research. The most important thing is that you have a confirmed diagnosis of EGPA. Your study doctor will check other medical details to make sure this study is right and safe for you.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- Você tem 18 anos ou mais?
- Do you have a confirmed diagnosis of Eosinophilic Granulomatosis with Polyangiitis (EGPA)?
- Você consegue comparecer a consultas regulares na clínica?
- Are you comfortable with the concept of being assigned a treatment by chance (randomly)?
- Have you discussed your current medications with your doctor?
O que envolve a participação?
If you decide to take part in this study, you would be randomly assigned to one of two treatment groups – either the group receiving the mepolizumab-based treatment or the group receiving standard treatment. This is done by chance, like flipping a coin, and neither you nor your doctor will know which group you are in (this is called 'double-blind').
Throughout the study, you would have regular visits to the clinic where doctors and nurses would monitor your health and examine you. You'd likely provide blood samples for tests, and your medication doses would be carefully adjusted. The study would last for over a year (364 days), with key assessments at 168 days and at the end. Your doctor will explain all the visits, tests, and medicines in detail.
Riscos e benefícios potenciais
Localizações (1)
- —Não verificadoFrança
Perguntas frequentes
What is EGPA?
EGPA (Eosinophilic Granulomatosis with Polyangiitis) is a rare condition that causes inflammation in various body parts, often affecting the lungs, skin, and nerves.
O que é prednisona?
Prednisone is a type of steroid medication often used to reduce inflammation. While effective, long-term use can have side effects.
What is mepolizumab (Nucala)?
Mepolizumab is a drug that aims to reduce inflammation by targeting specific white blood cells called eosinophils, which are often overactive in people with EGPA.
Why is this study 'double-blind'?
Double-blind means neither you nor your doctors will know which treatment you are receiving. This helps make the study results more reliable and fair.
Quanto tempo durará o estudo?
The main part of the study will last about a year (364 days) with regular check-ups and monitoring during that time.
Como saber mais
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Interessado em participar?
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.